MCID: PDT014
MIFTS: 36

Pediatric Ependymoma

Categories: Cancer diseases, Genetic diseases

Aliases & Classifications for Pediatric Ependymoma

MalaCards integrated aliases for Pediatric Ependymoma:

Name: Pediatric Ependymoma 12 15
Childhood Ependymoma 12
Familial Ependymoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5509
NCIt 50 C8578
UMLS 73 C1851584

Summaries for Pediatric Ependymoma

MalaCards based summary : Pediatric Ependymoma, also known as childhood ependymoma, is related to ependymoma and malignant ependymoma. An important gene associated with Pediatric Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways is Development NOTCH1-mediated pathway for NF-KB activity modulation. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to... more...

Related Diseases for Pediatric Ependymoma

Diseases related to Pediatric Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 29.9 MEN1 RELA
2 malignant ependymoma 9.2 ERCC5 LOXL3 RELA

Symptoms & Phenotypes for Pediatric Ependymoma

GenomeRNAi Phenotypes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.65 LOXL3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.65 BCAT1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.65 BCAT1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.65 BCAT1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.65 BCAT1 LOXL3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.65 BCAT1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.65 BCAT1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.65 BCAT1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.65 BCAT1
10 Downregulation of NFkappaB pathway GR00313-A 8.62 MEN1 RELA

MGI Mouse Phenotypes related to Pediatric Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 MEN1 RELA FBXW7 HEY2 LOXL3
2 growth/size/body region MP:0005378 9.73 MEN1 ERCC5 RELA FBXW7 HEY2 LOXL3
3 digestive/alimentary MP:0005381 9.72 MEN1 ERCC5 RELA FBXW7 LOXL3
4 craniofacial MP:0005382 9.67 MEN1 FBXW7 HEY2 LOXL3
5 liver/biliary system MP:0005370 9.55 ERCC5 RELA FBXW7 HEY2 MEN1
6 mortality/aging MP:0010768 9.43 MEN1 ERCC5 RELA FBXW7 HEY2 LOXL3
7 respiratory system MP:0005388 8.92 RELA FBXW7 HEY2 LOXL3

Drugs & Therapeutics for Pediatric Ependymoma

Drugs for Pediatric Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
2
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
6
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
7
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
8
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 52-24-4 5453
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
12
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
13
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
14
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
15
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
16
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dopamine Approved Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
20
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
23 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
27 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Liver Extracts Phase 3,Phase 2,Phase 1
35 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
41
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
42 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
43 Analgesics Phase 3,Phase 2,Phase 1
44 Adjuvants, Anesthesia Phase 3
45 Central Nervous System Stimulants Phase 3,Phase 2
46 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
47 GABA Agents Phase 2, Phase 3,Phase 1
48 Serotonin Agents Phase 3,Phase 2
49 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
50 Serotonin Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 liposomal vincristine sulfate;carboplatin;cyclophosphamide;etoposide;cisplatin
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
11 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
12 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
13 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
15 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
16 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
17 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
18 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
19 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
20 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
21 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
22 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
23 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
24 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
25 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
26 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
27 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
28 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
29 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
30 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
31 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
32 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
33 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
34 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
35 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
36 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
37 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
38 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
39 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
40 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
41 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
42 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
43 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
44 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
45 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
46 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
47 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
48 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
49 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
50 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate

Search NIH Clinical Center for Pediatric Ependymoma

Genetic Tests for Pediatric Ependymoma

Anatomical Context for Pediatric Ependymoma

MalaCards organs/tissues related to Pediatric Ependymoma:

41
Brain, Bone, Bone Marrow, Spinal Cord, T Cells, Testes, Liver

Publications for Pediatric Ependymoma

Articles related to Pediatric Ependymoma:

(show all 34)
# Title Authors Year
1
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. ( 29774098 )
2018
2
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. ( 29500084 )
2018
3
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. ( 29029279 )
2017
4
Outcomes following proton therapy for pediatric ependymoma. ( 29239262 )
2017
5
Novel SEC61G-EGFR Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens. ( 29092923 )
2017
6
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. ( 28437838 )
2017
7
Pediatric Ependymoma: A Proteomics Perspective. ( 28387652 )
2017
8
The Pediatric Ependymoma Protein Database (PEPD). ( 29124086 )
2017
9
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ( 27287856 )
2016
10
Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. ( 27386327 )
2016
11
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. ( 27104090 )
2016
12
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. ( 25724157 )
2015
13
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. ( 26500028 )
2015
14
Pediatric Ependymoma. ( 26503805 )
2015
15
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( 25120190 )
2014
16
Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. ( 24462384 )
2014
17
Endoscopic endonasal transclival approach to a ventral pontine pediatric ependymoma. ( 23992235 )
2013
18
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. ( 24077346 )
2013
19
Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression. ( 23371454 )
2013
20
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. ( 21627842 )
2011
21
Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. ( 21207372 )
2011
22
Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. ( 22192550 )
2011
23
Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma. ( 20347495 )
2010
24
Telomerase inhibition as a novel therapy for pediatric ependymoma. ( 20184588 )
2010
25
Pediatric ependymoma: biological perspectives. ( 19531565 )
2009
26
Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13. ( 18663750 )
2008
27
Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. ( 18179864 )
2008
28
Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. ( 18716553 )
2008
29
Contribution of NMR spectroscopy to the differential diagnosis of a recurrent cranial mass 7 years after irradiation for a pediatric ependymoma. ( 16708251 )
2006
30
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. ( 15701279 )
2005
31
Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. ( 12505253 )
2002
32
Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. ( 10451703 )
1999
33
Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. ( 9215786 )
1997
34
Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas? ( 1581886 )
1992

Variations for Pediatric Ependymoma

Expression for Pediatric Ependymoma

Search GEO for disease gene expression data for Pediatric Ependymoma.

Pathways for Pediatric Ependymoma

Pathways related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.03 FBXW7 HEY2 RELA

GO Terms for Pediatric Ependymoma

Biological processes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to UV GO:0009411 9.16 ERCC5 MEN1
2 negative regulation of Notch signaling pathway GO:0045746 8.96 FBXW7 HEY2
3 negative regulation of transcription, DNA-templated GO:0045892 8.92 HEY2 LOXL3 MEN1 RELA

Molecular functions related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.32 ERCC5 MEN1
2 histone deacetylase binding GO:0042826 9.26 HEY2 RELA
3 protein binding, bridging GO:0030674 9.16 FBXW7 MEN1
4 transcription factor activity, RNA polymerase II core promoter sequence-specific DNA binding GO:0000983 8.96 HEY2 RELA
5 protein N-terminus binding GO:0047485 8.8 ERCC5 MEN1 RELA

Sources for Pediatric Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....